Shares of Outlook Therapeutics sank 8.9% to $1.35 after a July 16 special shareholder meeting gave management sweeping new authority over the company's share structure — just as a make-or-break FDA ruling looms on July 29.
• Shareholders Just More Than Doubled the Company's Authorized Shares
Stockholders approved amending the certificate of incorporation to increase authorized common stock from 260 million to 600 million shares.
They also approved a reverse stock split at a ratio between 1-for-10 and 1-for-50, at the board's sole discretion. For existing investors, the combination is ominous: a reverse split would shrink the share count and push up the per-share price, but the vastly larger authorized pool means the board could later issue hundreds of millions of new shares — diluting (reducing the ownership stake of) current holders without asking them again.
• The Vote Barely Cleared the Room
Only about 62.3 million shares, roughly 51.5% of the 120.9 million outstanding, were present or represented by proxy.
On the authorized share increase, just 24.4 million shares voted in favor versus 8.7 million against, with nearly 29 million broker non-votes. That thin margin underscores tepid shareholder conviction in a capital structure overhaul that could reshape ownership.
• The Balance Sheet Is Running on Fumes
Outlook has less than a year of cash runway and carries negative shareholder equity of -$37.2 million with $34.4 million in total debt.
The company says these steps support needed fundraising and Nasdaq compliance but acknowledges potential dilution and reverse-split risks for existing holders.
Nasdaq warned the company in February 2026 after the stock traded below $1 for 30 consecutive days, with a cure deadline of August 17 requiring at least ten consecutive sessions above $1.
• An FDA Decision Could Upend the Calculus — Or Seal It
The company's resubmitted application for its eye-disease drug is under a Class 1 review, with the FDA's target action date set for July 29, 2026.
The FDA previously concluded that substantial evidence of effectiveness has been established. An approval would make the drug the first FDA-sanctioned version of a widely used eye treatment and could transform Outlook from a cash-burning shell into a commercial-stage business. A rejection would leave a company with negative equity scrambling to fund operations through yet more share sales — with 600 million authorized shares now at management's disposal.